S. Gilman, G. K. Wenning, and P. A. Low, Second consensus statement on the diagnosis of multiple system atrophy, Neurology, vol.71, issue.9, pp.670-676, 2008.

M. Lopez-cuina, A. Foubert-samier, F. Tison, and W. G. Meissner, Present and future of disease-modifying therapies in multiple system atrophy, Auton Neurosci, vol.211, pp.31-38, 2018.

F. Krismer and G. K. Wenning, Multiple system atrophy: insights into a rare and debilitating movement disorder, Nat Rev Neurol, vol.13, issue.4, pp.232-243, 2017.

M. I. Papp, J. E. Kahn, and P. L. Lantos, Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)

, J Neurol Sci, vol.94, issue.1-3, pp.79-100, 1989.

N. Quinn, Multiple system atrophy-the nature of the beast, J Neurol Neurosurg Psychiatry, vol.1989, pp.78-89

M. G. Spillantini, R. A. Crowther, R. Jakes, N. J. Cairns, P. L. Lantos et al., Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies, Neurosci Lett, vol.251, issue.3, pp.205-208, 1998.

D. W. Miller, J. M. Johnson, S. M. Solano, Z. R. Hollingsworth, D. G. Standaert et al., Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia, J Neural Transm, vol.112, issue.12, pp.1613-1624, 2005.

H. Jin, K. Ishikawa, T. Tsunemi, T. Ishiguro, T. Amino et al., Analyses of copy number and mRNA expression level of the alphasynuclein gene in multiple system atrophy, J Med Dent Sci, vol.55, issue.1, pp.145-153, 2008.

P. O. Fernagut and F. Tison, Animal models of multiple system atrophy, Neuroscience, vol.211, pp.77-82, 2012.

P. J. Kahle, M. Neumann, and L. Ozmen, Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes, EMBO Rep, vol.3, issue.6, pp.583-588, 2002.

C. W. Shults, E. Rockenstein, and L. Crews, Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy, J Neurosci, vol.25, issue.46, pp.10689-10699, 2005.

I. Yazawa, B. I. Giasson, and R. Sasaki, Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration, Neuron, vol.45, issue.6, pp.847-859, 2005.

S. Gilman, P. A. Low, and N. Quinn, Consensus statement on the diagnosis of multiple system atrophy, J Neurol Sci, vol.163, issue.1, pp.94-98, 1999.

A. Schrag, C. D. Good, and K. Miszkiel, Differentiation of atypical parkinsonian syndromes with routine MRI, Neurology, vol.54, issue.3, pp.697-702, 2000.

G. K. Wenning, F. Tison, and K. Seppi, Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)

, Mov Disord, vol.19, issue.12, pp.1391-1402, 2004.

A. Schrag, C. Selai, and C. Mathias, Measuring health-related quality of life in MSA: the MSA-QoL, Mov Disord, vol.22, issue.16, pp.2332-2338, 2007.

B. Holmberg, J. O. Johansson, and W. Poewe, Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study, Mov Disord, vol.22, issue.8, pp.1138-1144, 2007.

B. Laurens, S. Vergnet, and M. C. Lopez, Multiple System Atrophy -State of the Art, Curr Neurol Neurosci Rep, vol.17, issue.5, p.41, 2017.

Y. T. Asi, J. E. Simpson, and P. R. Heath, Alpha-synuclein mRNA expression in oligodendrocytes in MSA, Glia, vol.62, issue.6, pp.964-970, 2014.

M. Djelloul, S. Holmqvist, and A. Boza-serrano, Alpha-Synuclein Expression in the Oligodendrocyte Lineage: an in vitro and in vivo Study Using Rodent and Human Models, Stem Cell Reports, 2015.

P. Desplats, H. J. Lee, and E. J. Bae, Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein, Proc Natl Acad Sci U S A, vol.106, issue.31, pp.13010-13015, 2009.

E. Rockenstein, K. Ubhi, and C. Inglis, Neuronal to oligodendroglial alpha-synuclein redistribution in a double transgenic model of multiple system atrophy, Neuroreport, vol.23, issue.4, pp.259-264, 2012.

H. Kisos, K. Pukass, T. Ben-hur, C. Richter-landsberg, and S. R. , Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies, PLoS One, vol.7, issue.10, p.46817, 2012.

K. C. Luk, V. Kehm, and J. Carroll, Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science, vol.338, issue.6109, pp.949-953, 2012.

F. Cavaliere, L. Cerf, and B. Dehay, In vitro alpha-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains, Neurobiol Dis, vol.103, pp.101-112, 2017.

J. Rostami, S. Holmqvist, and V. Lindstrom, Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes, J Neurosci, vol.37, issue.49, pp.11835-11853, 2017.

C. Hansen, E. Angot, and A. L. Bergstrom, alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells, J Clin Invest, vol.121, issue.2, pp.715-725, 2011.

J. F. Reyes, N. L. Rey, L. Bousset, R. Melki, P. Brundin et al., Alphasynuclein transfers from neurons to oligodendrocytes, Glia, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01181201

S. Kaji, T. Maki, and H. Kinoshita, Pathological Endogenous alpha-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy, Stem Cell Reports, vol.10, issue.2, pp.356-365, 2018.

V. E. May, B. Ettle, and A. M. Poehler, alpha-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy, Neurobiol Aging, vol.35, issue.10, pp.2357-2368, 2014.

Y. J. Song, D. M. Lundvig, and Y. Huang, p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy, Am J Pathol, vol.171, issue.4, pp.1291-1303, 2007.

K. Ota, M. Obayashi, and K. Ozaki, Relocation of p25alpha/tubulin polymerization promoting protein from the nucleus to the perinuclear cytoplasm in the oligodendroglia of sporadic and COQ2 mutant multiple system atrophy, Acta Neuropathol Commun, vol.2, p.136, 2014.

P. Mavroeidi, F. Arvanitaki, and A. K. Karakitsou, Endogenous oligodendroglial alpha-synuclein and TPPP/p25alpha orchestrate alpha-synuclein pathology in experimental multiple system atrophy models, Acta Neuropathol, vol.138, issue.3, pp.415-441, 2019.

S. B. Prusiner, A. L. Woerman, and D. A. Mordes, Evidence for alphasynuclein prions causing multiple system atrophy in humans with parkinsonism, Proc Natl Acad Sci, vol.112, issue.38, pp.5308-5317, 2015.

J. C. Watts, K. Giles, and A. Oehler, Transmission of multiple system atrophy prions to transgenic mice, Proc Natl Acad Sci U S A, vol.110, issue.48, pp.19555-19560, 2013.

A. L. Woerman, S. A. Kazmi, and S. Patel, MSA prions exhibit remarkable stability and resistance to inactivation, Acta Neuropathol, vol.135, issue.1, pp.49-63, 2018.

W. Peelaerts, L. Bousset, and A. Van-der-perren, alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration, Nature, vol.522, issue.7556, pp.340-344, 2015.

C. Peng, R. J. Gathagan, and D. J. Covell, Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies, Nature, vol.557, issue.7706, pp.558-563, 2018.

J. S. Dhillon, J. A. Trejo-lopez, and C. Riffe, Comparative analyses of the in vivo induction and transmission of alpha-synuclein pathology in transgenic mice by MSA brain lysate and recombinant alpha-synuclein fibrils, Acta Neuropathol Commun, vol.7, issue.1, p.80, 2019.

G. Wenning, J. Q. Trojanowski, H. Kaufmann, T. Wisniewski, W. A. Rocca et al., Is multiple system atrophy an infectious disease?, Ann Neurol, vol.83, issue.1, pp.10-12, 2018.

J. E. Duda, B. I. Giasson, and T. L. Gur, Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy, J Neuropathol Exp Neurol, vol.59, issue.9, pp.830-841, 2000.

B. C. Campbell, C. A. Mclean, and J. G. Culvenor, The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease, J Neurochem, vol.76, issue.1, pp.87-96, 2001.

K. Tanji, Y. Miki, and F. Mori, A mouse model of adult-onset multiple system atrophy, Neurobiol Dis, vol.127, pp.339-349, 2019.

F. Bassil, P. A. Guerin, and N. Dutheil, Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy, Mov Disord, vol.32, issue.8, pp.1230-1239, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01537940

R. J. Mandel, D. J. Marmion, and D. Kirik, Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates, Acta Neuropathol Commun, vol.5, issue.1, p.47, 2017.

O. Flabeau, W. G. Meissner, A. Ozier, P. Berger, F. Tison et al., Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy, Mov Disord, vol.29, issue.3, pp.388-395, 2014.

M. Boudes, P. Uvin, and S. Pinto, Bladder dysfunction in a transgenic mouse model of multiple system atrophy, Mov Disord, vol.28, issue.3, pp.347-355, 2013.

D. Kuzdas, S. Stemberger, S. Gaburro, N. Stefanova, N. Singewald et al., Oligodendroglial alpha-synucleinopathy and MSAlike cardiovascular autonomic failure: experimental evidence, Exp Neurol, vol.247, pp.531-536, 2013.

M. Federoff, T. R. Price, and A. Sailer, Genome-wide estimate of the heritability of Multiple System Atrophy, Parkinsonism Relat Disord, vol.22, pp.35-41, 2016.

A. Sailer, S. W. Scholz, and M. A. Nalls, Multiple-System Atrophy Research C. Mutations in COQ2 in familial and sporadic multiple-system atrophy, N Engl J Med, vol.87, issue.15, pp.233-244, 2013.

B. S. Jeon, M. J. Farrer, and S. F. Bortnick, Korean Canadian Alliance on Parkinson's D, Related D. Mutant COQ2 in multiple-system atrophy, N Engl J Med, vol.371, issue.1, p.80, 2014.

C. H. Lin, E. K. Tan, C. C. Yang, Z. Yi, and R. M. Wu, COQ2 gene variants associate with cerebellar subtype of multiple system atrophy in Chinese, Mov Disord, vol.30, issue.3, pp.436-437, 2015.

K. Ogaki, S. Fujioka, and M. G. Heckman, Analysis of COQ2 gene in multiple system atrophy, Mol Neurodegener, vol.9, p.44, 2014.

D. Ronchi, D. Biase, E. Franco, and G. , Mutational analysis of COQ2 in patients with MSA in Italy, Neurobiol Aging, vol.45, pp.213-211, 2016.

L. V. Schottlaender and H. Houlden, Multiple-System Atrophy Brain Bank C. Mutant COQ2 in multiple-system atrophy, N Engl J Med, vol.371, issue.1, p.81, 2014.

M. Sharma, G. Wenning, and R. Kruger, European Multiple-System Atrophy Study G. Mutant COQ2 in multiple-system atrophy, N Engl J Med, vol.371, issue.1, pp.80-81, 2014.

Z. Sun, Y. Ohta, and T. Yamashita, New susceptible variant of COQ2 gene in Japanese patients with sporadic multiple system atrophy, Neurol Genet, vol.2, issue.2, p.54, 2016.

R. Procopio, M. Gagliardi, and L. Brighina, Genetic mutation analysis of the COQ2 gene in Italian patients with multiple system atrophy, Gene, pp.20-144037, 2019.

K. Mokretar, D. Pease, and J. W. Taanman, Somatic copy number gains of alpha-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains, Brain, vol.141, issue.8, pp.2419-2431, 2018.

M. G. Heckman, L. Schottlaender, and A. I. Soto-ortolaza, LRRK2 exonic variants and risk of multiple system atrophy, Neurology, vol.83, issue.24, pp.2256-2261, 2014.

L. J. Ozelius, T. Foroud, and S. May, G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy, Mov Disord, vol.22, issue.4, pp.546-549, 2007.

G. M. Riboldi, J. A. Palma, and E. Cortes, Early-onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation, Mov Disord, vol.34, issue.7, pp.1080-1082, 2019.

J. Mitsui, T. Matsukawa, and H. Sasaki, Variants associated with Gaucher disease in multiple system atrophy, Ann Clin Transl Neurol, vol.2, issue.4, pp.417-426, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01122349

M. Sklerov, U. J. Kang, and C. Liong, Frequency of GBA variants in autopsy-proven multiple system atrophy, Mov Disord Clin Pract, vol.4, issue.4, pp.574-581, 2017.

P. Pasanen, L. Myllykangas, and M. Siitonen, Novel alphasynuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology, Neurobiol Aging, vol.35, issue.9, pp.2180-2181, 2014.

A. P. Kiely, Y. T. Asi, and E. Kara, alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?, Acta Neuropathol, vol.125, issue.5, pp.753-769, 2013.

M. Stamelou, N. P. Quinn, and K. P. Bhatia, Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide, Mov Disord, vol.28, issue.9, pp.1184-1199, 2013.

I. Stankovic, N. Quinn, and L. Vignatelli, A critique of the second consensus criteria for multiple system atrophy, Mov Disord, 2019.

A. Cortese, R. Simone, and R. Sullivan, Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia, Nat Genet, vol.51, issue.4, pp.649-658, 2019.

M. Kollensperger, F. Geser, and J. P. Ndayisaba, Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry, Mov Disord, vol.25, issue.15, pp.2604-2612, 2010.

Y. Osaki, Y. Ben-shlomo, A. J. Lees, G. K. Wenning, and N. P. Quinn, A validation exercise on the new consensus criteria for multiple system atrophy, Mov Disord, vol.24, issue.15, pp.2272-2276, 2009.

S. Koga, N. Aoki, and R. J. Uitti, When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients, Neurology, vol.85, issue.5, pp.404-412, 2015.

Y. Miki, S. C. Foti, and Y. T. Asi, Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study, Brain, vol.142, issue.9, pp.2813-2827, 2019.

H. Watanabe, Y. Saito, and S. Terao, Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients, Brain, vol.125, pp.1070-1083, 2002.

H. J. Kim, B. S. Jeon, J. Y. Lee, and J. Y. Yun, Survival of Korean patients with multiple system atrophy, Mov Disord, vol.26, issue.5, pp.909-912, 2011.

E. A. Coon, D. M. Sletten, and M. D. Suarez, Clinical features and autonomic testing predict survival in multiple system atrophy, Brain, vol.138, pp.3623-3631, 2015.

H. Kaufmann, L. Norcliffe-kaufmann, and J. A. Palma, Natural history of pure autonomic failure: A United States prospective cohort, Ann Neurol, vol.81, issue.2, pp.287-297, 2017.

W. Singer, S. E. Berini, and P. Sandroni, Pure autonomic failure: Predictors of conversion to clinical CNS involvement, Neurology, vol.88, issue.12, pp.1129-1136, 2017.

E. A. Coon, R. D. Fealey, and D. M. Sletten, Anhidrosis in multiple system atrophy involves pre-and postganglionic sudomotor dysfunction, Mov Disord, vol.32, issue.3, pp.397-404, 2017.

S. Orimo, T. Kanazawa, and A. Nakamura, Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy, Acta Neuropathol, vol.113, issue.1, pp.81-86, 2007.

H. Nagayama, M. Ueda, M. Yamazaki, Y. Nishiyama, M. Hamamoto et al., Abnormal cardiac [(123)I]-metaiodobenzylguanidine uptake in multiple system atrophy, Mov Disord, vol.25, issue.11, pp.1744-1747, 2010.

V. Provitera, M. Nolano, and G. Caporaso, Postganglionic sudomotor denervation in patients with multiple system atrophy, Neurology, vol.82, issue.24, pp.2223-2229, 2014.

D. S. Goldstein and W. P. Cheshire, Roles of cardiac sympathetic neuroimaging in autonomic medicine, Clin Auton Res, vol.28, issue.4, pp.397-410, 2018.

K. Doppler, J. Weis, and K. Karl, Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy, Mov Disord, vol.30, issue.12, pp.1688-1692, 2015.

L. Zange, C. Noack, K. Hahn, W. Stenzel, and A. Lipp, Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy, Brain, vol.138, pp.2310-2321, 2015.

I. Stankovic, F. Krismer, and A. Jesic, Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group, Mov Disord, vol.29, issue.7, pp.857-867, 2014.

F. Ory-magne, J. Pellaprat, and E. Harroch, Abnormal pain perception in patients with Multiple System Atrophy, Parkinsonism Relat Disord, vol.48, pp.28-33, 2018.

L. M. Benrud-larson, P. Sandroni, A. Schrag, and P. A. Low, Depressive symptoms and life satisfaction in patients with multiple system atrophy, Mov Disord, vol.20, issue.8, pp.951-957, 2005.

D. S. Goldstein, C. Holmes, and O. Bentho, Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy, Parkinsonism Relat Disord, vol.14, issue.8, pp.600-607, 2008.

F. Krismer, B. Pinter, and C. Mueller, Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism, Parkinsonism Relat Disord, vol.35, pp.36-41, 2017.

M. Suzuki, M. Hashimoto, M. Yoshioka, M. Murakami, K. Kawasaki et al., The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy, BMC Neurol, vol.11, p.157, 2011.

H. J. Huppertz, L. Moller, and M. Sudmeyer, Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification, Mov Disord, vol.31, issue.10, pp.1506-1517, 2016.

C. Scherfler, G. Gobel, and C. Muller, Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism, Neurology, vol.86, issue.13, pp.1242-1249, 2016.

G. Barbagallo, M. Sierra-pena, and F. Nemmi, Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease, Mov Disord, vol.31, issue.3, pp.325-334, 2016.

P. Peran, G. Barbagallo, and F. Nemmi, MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy, Mov Disord, vol.33, issue.4, pp.600-608, 2018.

F. Krismer, K. Seppi, and G. Gobel, Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis, Mov Disord, vol.34, issue.7, pp.1041-1048, 2019.

F. Nemmi, A. Pavy-le-traon, and O. R. Phillips, A totally datadriven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control, Neuroimage Clin, vol.23, p.101858, 2019.

S. Vergnet, F. Hives, and A. Foubert-samier, Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type, Parkinsonism Relat Disord, vol.63, pp.190-203, 2019.

T. Ozawa, D. Paviour, and N. P. Quinn, The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations, Brain, vol.127, pp.2657-2671, 2004.

C. C. Tang, K. L. Poston, and T. Eckert, Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis, Lancet Neurol, vol.9, issue.2, pp.149-158, 2010.

T. Eckert, C. Tang, and Y. Ma, Abnormal metabolic networks in atypical parkinsonism, Mov Disord, vol.23, issue.5, pp.727-733, 2008.

K. L. Poston, C. C. Tang, and T. Eckert, Network correlates of disease severity in multiple system atrophy, Neurology, vol.78, issue.16, pp.1237-1244, 2012.

M. Tripathi, C. C. Tang, and A. Feigin, Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study, J Nucl Med, vol.57, issue.1, pp.60-66, 2016.

F. Holtbernd, J. F. Gagnon, and R. B. Postuma, Abnormal metabolic network activity in REM sleep behavior disorder, Neurology, 2014.

B. Laurens, R. Constantinescu, and R. Freeman, Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative, Neurobiol Dis, vol.80, pp.29-41, 2015.

P. A. Low, S. G. Reich, and J. Jankovic, Natural history of multiple system atrophy in the USA: a prospective cohort study, Lancet Neurol, vol.14, issue.7, pp.710-719, 2015.

G. K. Wenning, F. Geser, and F. Krismer, The natural history of multiple system atrophy: a prospective European cohort study, Lancet Neurol, vol.12, issue.3, pp.264-274, 2013.

Y. Ben-shlomo, G. K. Wenning, F. Tison, and N. P. Quinn, Survival of patients with pathologically proven multiple system atrophy: a meta-analysis, Neurology, vol.48, issue.2, pp.384-393, 1997.

S. S. O'sullivan, L. A. Massey, and D. R. Williams, Clinical outcomes of progressive supranuclear palsy and multiple system atrophy, Brain, vol.131, pp.1362-1372, 2008.

A. Schrag, G. K. Wenning, N. Quinn, and Y. Ben-shlomo, Survival in multiple system atrophy, Mov Disord, vol.23, issue.2, pp.294-296, 2008.

C. Starhof, L. Korbo, C. F. Lassen, K. Winge, and S. Friis, Clinical Features in a Danish Population-Based Cohort of Probable Multiple System Atrophy Patients, Neuroepidemiology, vol.46, issue.4, pp.261-267, 2016.

I. N. Petrovic, H. Ling, and Y. Asi, Multiple system atrophyparkinsonism with slow progression and prolonged survival: a diagnostic catch, Mov Disord, vol.27, issue.9, pp.1186-1190, 2012.

W. G. Meissner, C. Laurencin, and C. Tranchant, Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature, Parkinsonism Relat Disord, vol.24, pp.69-75, 2016.

G. Giannini, G. Calandra-buonaura, and F. Mastrolilli, Early stridor onset and stridor treatment predict survival in 136 patients with MSA, Neurology, vol.87, issue.13, pp.1375-1383, 2016.

A. Fanciulli, J. Jordan, and I. Biaggioni, Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH), Clin Auton Res, vol.28, issue.4, pp.355-362, 2018.

W. Poewe, K. Seppi, and C. J. Fitzer-attas, Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial, Lancet Neurol, vol.14, issue.2, pp.145-152, 2015.

P. H. Lee, J. E. Lee, and H. S. Kim, A randomized trial of mesenchymal stem cells in multiple system atrophy, Ann Neurol, vol.72, issue.1, pp.32-40, 2012.

W. G. Meissner, A. Pavy-le-traon, and A. Foubert-samier, Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE ® PD01A and PD03A: results from the AFF009 phase I trial, Mov Disord, vol.33, issue.2, 2018.

K. Seppi, M. F. Schocke, and K. J. Mair, Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study, Neuroimage, vol.31, issue.1, pp.240-245, 2006.

D. C. Paviour, S. L. Price, M. Jahanshahi, A. J. Lees, and N. C. Fox, Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy, Brain, vol.129, pp.1040-1049, 2006.

M. T. Pellecchia, P. Barone, and C. Vicidomini, Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study, Mov Disord, vol.26, issue.7, pp.1303-1309, 2011.

Y. Horimoto, I. Aiba, and T. Yasuda, Cerebral atrophy in multiple system atrophy by MRI, J Neurol Sci, vol.173, issue.2, pp.109-112, 2000.

M. Konagaya, Y. Konagaya, M. Sakai, Y. Matsuoka, and Y. Hashizume, Progressive cerebral atrophy in multiple system atrophy, J Neurol Sci, vol.195, issue.2, pp.123-127, 2002.

T. K. Hauser, A. Luft, and M. Skalej, Visualization and quantification of disease progression in multiple system atrophy, Mov Disord, vol.21, issue.10, pp.1674-1681, 2006.

J. H. Lee, T. H. Kim, C. W. Mun, T. H. Kim, and Y. H. Han, Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes, J Neurol, vol.262, issue.8, pp.1876-1882, 2015.

W. Reginold, A. E. Lang, C. Marras, C. Heyn, M. Alharbi et al., Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy, Parkinsonism Relat Disord, vol.20, issue.2, pp.222-225, 2014.

J. Levin, S. Maass, and M. Schuberth, Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial, Lancet Neurol, vol.18, issue.8, pp.724-735, 2019.

E. B. Johnson, L. M. Byrne, and S. Gregory, Neurofilament light protein in blood predicts regional atrophy in Huntington disease, Neurology, vol.90, issue.8, pp.717-723, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01792038

C. H. Lu, C. Macdonald-wallis, and E. Gray, Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis, Neurology, vol.84, issue.22, pp.2247-2257, 2015.

J. C. Rojas, J. Bang, and I. V. Lobach, CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP, Neurology, vol.90, issue.4, pp.273-281, 2018.

J. C. Rojas, A. Karydas, and J. Bang, Plasma neurofilament light chain predicts progression in progressive supranuclear palsy, Ann Clin Transl Neurol, vol.3, issue.3, pp.216-225, 2016.

S. Perez-lloret, O. Flabeau, and P. O. Fernagut, Current Concepts in the Treatment of Multiple System Atrophy, Mov Disord Clin Pract, vol.2, issue.1, pp.6-16, 2015.

F. Bassil, P. O. Fernagut, and E. Bezard, Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy, Proc Natl Acad Sci, vol.113, issue.34, pp.9593-9598, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01370967

A. Heras-garvin, D. Weckbecker, and S. Ryazanov, Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy, Mov Disord, vol.34, issue.2, pp.255-263, 2019.

M. Mandler, E. Valera, and E. Rockenstein, Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy, Mol Neurodegener, vol.10, p.10, 2015.

E. Valera, B. Spencer, and J. A. Fields, Combination of alphasynuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy, Acta Neuropathol Commun, vol.5, issue.1, p.2, 2017.

M. Herrera-vaquero, D. Bouquio, and M. Kallab, The molecular tweezer CLR01 reduces aggregated, pathologic, and seedingcompetent alpha-synuclein in experimental multiple system atrophy, Biochim Biophys Acta Mol Basis Dis, vol.1865, issue.11, p.166513, 2019.

B. Spencer, E. Valera, E. Rockenstein, M. Trejo-morales, A. Adame et al., A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy, Mol Neurodegener, vol.10, p.48, 2015.

M. L. Arotcarena, M. Bourdenx, and N. Dutheil, Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies, JCI Insight, vol.4, issue.16, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02346929

B. Ettle, B. E. Kerman, and E. Valera, alpha-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy, Acta Neuropathol, vol.132, issue.1, pp.59-75, 2016.

F. Bassil, M. H. Canron, and A. Vital, Insulin resistance and exendin-4 treatment for multiple system atrophy, Brain, vol.140, issue.5, pp.1420-1436, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01537233

S. Venezia, V. Refolo, A. Polissidis, L. Stefanis, G. K. Wenning et al., Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal alpha-synucleinopathy

, Mol Neurodegener, vol.12, issue.1, p.52, 2017.

E. Sturm, L. Fellner, F. Krismer, W. Poewe, G. K. Wenning et al., Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy, Neurotherapeutics, vol.13, issue.4, pp.871-879, 2016.

N. Stefanova, Translational therapies for multiple system atrophy: Bottlenecks and future directions, Auton Neurosci, vol.211, pp.7-14, 2018.

R. Dodel, A. Spottke, and A. Gerhard, Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial), Mov Disord, vol.25, issue.1, pp.97-107, 2010.

G. Bensimon, A. Ludolph, and Y. Agid, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study, Brain, vol.132, pp.156-171, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00603311

P. A. Low, D. Robertson, and S. Gilman, Efficacy and safety of rifampicin for multiple system atrophy: a randomised, doubleblind, placebo-controlled trial, Lancet Neurol, vol.13, issue.3, pp.268-275, 2014.

J. A. Mullen, A. B. Savage, and C. Minkwitz, Safety, biomarker effects, and efficacy of the myeloperoxidase inhibitor AZD3241in patients with multiple system atrophy: a 12-week randomized multicenter PET study, Clin Auton Res, vol.28, p.144, 2018.

O. Rascol, M. French, and . Group, Preliminary results of the French MSA fluoxetine study, Eur J Neurol, vol.19, issue.1, p.262, 2012.

W. Singer, A. B. Dietz, and A. D. Zeller, Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy, Neurology, vol.93, issue.1, pp.77-87, 2019.

C. G. Goetz, B. C. Tilley, and S. R. Shaftman, Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results, Mov Disord, vol.23, issue.15, pp.2129-2170, 2008.

R. R. Walsh, F. Krismer, and W. R. Galpern, Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting, Neurology, vol.90, issue.2, pp.74-82, 2018.

P. O. Fernagut, B. Dehay, and A. Maillard, Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies, Neurobiol Dis, vol.67, pp.133-139, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01217333

B. Dehay, M. Bourdenx, and P. Gorry, Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations, Lancet Neurol, vol.14, issue.8, pp.855-866, 2015.